As of the latest Form 4 filed Jun 24, 2026.
What Arcus Biosciences Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 15 most recent filings for RCUS.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-24 | 2026-06-24 | Jaen Juan C. President | SSale | −6.43K | $29.66 | $191K | Yes (planned) | Form 4 ↗ |
| 2026-06-24 | 2026-06-23 | Jaen Juan C., President | SSale | −1.70K | $28.06 | $47.6K | Yes (planned) | Form 4 ↗ |
| 2026-06-24 | 2026-06-23 | Jaen Juan C., President | SSale | −14.1K | $27.69 | $389K | Yes (planned) | Form 4 ↗ |
| 2026-06-24 | 2026-06-22 | Jaen Juan C., President | SSale | −9.24K | $27.03 | $250K | Yes (planned) | Form 4 ↗ |
| 2026-06-12 | 2026-06-11 | Tang Carolyn C. General Counsel | MExercise | +34.1K | $2.57 | $87.7K | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-11 | Ribas Antoni Director | AAward | +5.70K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-11 | Lambert Nicole Director | AAward | +5.70K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-11 | Lacey David L. Director | AAward | +5.70K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-11 | Machado Patrick Director | AAward | +5.70K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-11 | KANEKO YASUNORI Director | AAward | +5.70K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-11 | FALBERG KATHRYN E Director | AAward | +5.70K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-11 | PERLMAN ANDREW J Director | AAward | +5.70K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-01 | 2026-06-01 | Azoy Alexander Chief Accounting Officer | SSale | −2.56K | $25.77 | $66.0K | Yes (planned) | Form 4 ↗ |
| 2026-05-12 | 2026-05-11 | Goeltz II Robert C. Chief Financial Officer | SSale | −7.76K | $25.63 | $199K | Yes (planned) | Form 4 ↗ |
| 2026-05-12 | 2025-12-16 | Ribas Antoni Director | GGift | −5.05K | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also RCUS’s full analysis or the market-wide insider trading feed. The tabs above jump to RCUS’s other SEC data.
Source: SEC Form 4 filings for RCUS, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.